Skip to main content
OpenTrials
Completed

NCT Number: NCT04346693

An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19

The purpose of the study is to evaluate an effectiveness of the drug Dalargin in combination with Leitragin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical coronavirus infection cases (SARS COVID19, expanded as Severe acute respiratory syndrome Cоrona Virus Disease 2019 ).

Test drugs that will be administered to patients are:

* Leitragin, solution for inhalation administration, * Dalargin, solution for intravenous and intramuscular administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Respiratory Tract Infection Acute Respiratory Insufficiency Hypoxemia Hypoxia Infections Inflammation Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Respiratory Tract Diseases Respiratory Tract Infections Sepsis Septic Shock Shock Shock, Septic Signs and Symptoms Signs and Symptoms, Respiratory Systemic Inflammatory Response Syndrome

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Burnasyan Federal Medical Biophysical Center FMBA of Russia

Moscow, 123098, Russia

About this study

Research objectives are:

  • To study the effectiveness of the drug Leitragin, a solution for inhalation, for the prevention of severe pulmonary complications in patients with coronavirus infection (SARS-COVID-19);
  • To study the effectiveness of the drug Leitragin, a solution for inhalation, for the treatment of severe pulmonary complications in patients with coronavirus infection (SARS-COVID-19);
  • To study the effectiveness of the drug Dalargin, a solution for intravenous and intramuscular administration, for the prevention of severe pulmonary complications in patients with coronavirus infection (SARS-COVID-19);
  • To study the effectiveness of the drug Dalargin, a solution for intravenous and intramuscular administration, for the treatment of severe pulmonary complications in patients with coronavirus infection (SARS-COVID-19);
  • To evaluate the safety and tolerability of the use of the drug Leitragin, a solution for inhalation administration, for the prevention of severe pulmonary complications in patients with coronavirus infection (SARS-COVID-19);
  • To evaluate the safety and tolerability of the use of the drug Leitragin, a solution for inhalation administration, for the treatment of severe pulmonary complications in patients with coronavirus infection (SARS-COVID-19);
  • To evaluate the safety and tolerability of the use of the drug Dalargin, a solution for intravenous and intramuscular administration, for the prevention of severe pulmonary complications in patients with coronavirus infection (SARS-COVID-19);
  • To evaluate the safety and tolerability of the use of the drug Dalargin, a solution for intravenous and intramuscular administration, for the treatment of severe pulmonary complications in patients with coronavirus infection (SARS-COVID-19).

Upon admission to a specialized hospital for all patients with suspected COVID-19 Polymerase chain reaction (PCR) is being conducted. Only patients with confirmed coronavirus infection are included in the study.

It is an open, randomized clinical trial of the drug Dalargin in combination with Leitragin for the prevention and treatment of severe pulmonary complications symptoms in patients with coronavirus infection (SARS-COVID-19)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients from the age of 18 years male and female;
  • Coronavirus infection confirmed by results of Polymerase chain reaction test;
  • Hospitalization of the patient;
  • The presence of a signed informed consent to participate in the study.

Exclusion criteria

  • Revocation of informed consent by the patient.
  • Patient mismatch inclusion criteria.
  • First identified conditions and / or diseases described in the non-inclusion criteria.

The criteria for early termination of patient participation in the study during the period of use of the study drug are:

  • Patient withdrawal of informed consent.
  • First identified conditions and / or diseases described in the non-inclusion criteria.
  • The occurrence of serious adverse events.
  • Adverse events that do not meet the criteria of severity, the development of which, according to the researcher, further participation in the study may be detrimental to the health or well-being of the patient.
  • Administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as gross protocol violations that may affect the results of the study.
  • The patient receives / needs additional treatment that may affect the outcome of the study or patient safety
  • Individual intolerance to research drugs
  • Incorrect inclusion (for example, the patient was included in violation of the criteria for inclusion / non-inclusion of the protocol)

Treatment and study plan

Standard therapy recommended by the Ministry of Health of the Russian Federation.

Procedure

Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.

For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.

For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days

Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection

Procedure

Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.

For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.

For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.

Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days

Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation

Procedure

Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.

For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.

For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.

Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.

Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation

Procedure

Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.

For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.

For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.

Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.

Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days

Primary outcomes

  1. The change of viral load in patients with SARS-COVID-19.

    Time frame: Upon patient inclusion in the study, after 96 hours and on the 10day;

    Estimated by Polymerase chain reaction (PCR)

  2. The frequency of development of Acute Respiratory Distress Syndrome (ADRS)

    Time frame: up to 10 days

    Assessed through the entire patient participation in the study

  3. Duration of hospitalization

    Time frame: up to 10 days

    The number of days a patient is hospitalized

  4. The frequency of early mortality

    Time frame: up to 30 days

    Early mortality from all causes will be estimated

  5. The frequency of late mortality

    Time frame: up to 90 days

    Late mortality from all causes will be estimated

  6. Clinical status at the time of completion of participation in the study

    Time frame: an average of 10 days

    Clinical status at the time of completion of participation in the study will be estimated based upon the following criteria:

    • Death;
    • Hospitalization is extended, on invasive mechanical ventilation of the lungs with extracorporeal membrane oxygenation;
    • Hospitalization extended, on non-invasive ventilation;
    • Hospitalization is extended, needs additional oxygen;
    • Hospitalization is extended, additional oxygen is not required;
    • Discharged.

Sponsors and collaborators

Lead sponsor

Burnasyan Federal Medical Biophysical Center

Other Gov

Registry information

Official study title

An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19)

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 15, 2020
Registry last updated
Oct 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.